Your comments are very intriguing. Question regarding a government contract to stockpile bavi. Didn't SK say on the last CC that Avid already has commitments for it's entire capacity through the end of 2009? How do you think they could make a new contract like this work in the near term?
If that's the plan ie run a Ph II-III hans solo, then I expect the company to fill up the tank with the $7.5 mil shelf and $5 add debt. So some dilution say 3% to 6%, and the company kills its own rally again.
One question, if all these things start actually happening, why wouldn't BP try a hostile takeover? Right now shareholders are worn out and ready for change.
BOT, sounds great. Do we have any indication how soon we may be hearing about a stockpiling deal? I would think shortly if they are going to bein preparing for a submittal of a phase 2-3 of 300 to the FDA. they must be pretty sure of the SP deal to let their cash level shrink to the level it is.
Thanks, BOT. SK clearly was optimistic about Animal Rule approval of Bavi for Lassa (and subsequent Gov’t Stockpiling) back in the BioWorld interview, just after the DTRA announcement.
Now, check his 3-12-09 CC comments on the same subject – see below.
“Efficacy in relevant Animal models” + “Phase I safety trials in humans” = Animal Rule Approval. We’re at 160+ now treated with Bavi. Fingers X’d…
BIOWORLD Today - Jul. 03, 2008 ( http://tinyurl.com/5kr6xk ) … The company could be in Phase III testing for breast cancer and potentially lung cancer as early as next year if Phase II results are positive, King said. The solid tumors will more than likely be the first indication Peregrine seeks, he noted. However, because of the expedited process in developing products under the govt's animal efficacy rule, the viral hemorrhagic fevers indication potentially could be the first approved use for Bavituximab… The DTRA dev. program, he said, "naturally dovetails" with Peregrine's ongoing development efforts for bavituximab in treating viruses. Part of the biodefense contract funds, King said, will aid Peregrine in scaling up its production and testing for the antibody, which he said will assist in advancing bavituximab's other clinical areas. The other portion of the funding is geared directly toward dev. & testing specifically for the viral hemorrhagic fevers indication, he added. King said it is expected that the military may stockpile Bavituximab as part of its biodefense program, which potentially could result in a long-term partnership for Peregrine with the gov’t and future deals. The DTRA contract, King said, not only brings more dollars to the firm's development pgm, but "outside validation" for Peregrine's technology and product pipeline. "This is a situation where it is good for us and good for the gov’t," he said.
3-12-09 CC, CEO Steven King: PUBLICATIONS & PARTNERING INTEREST As I noted in the introduction, we were also very pleased to have Nature-Medicine publish our ground-breaking experiments using our Anti-PS antibodies to fight and cure lethal virus infections. Besides being well-received by research scientists as a fresh perspective on anti-viral therapy, the article also caught the eye of other top-tier medical journals, which subsequently produced reviews of our experiments. This is significant, because these studies are particularly relevant for our ongoing contract with the DTRA. Since large, controlled studies of deadly Hemorrhagic viruses in humans [ex: Lassa, Ebola, Marburg…] are obviously not possible, data from animal models of disease becomes extremely important. When combined with the drug’s human safety data, this becomes the potential basis [ie, “Animal Rule”] for eventual commercialization of the product. I also want to reiterate that as a result of our clinical developments and the research article that came out in Nature-Medicine, we have continued to see a significant uptick in partnering activity & interest. We have always maintained that the success of partnering will be driven by positive clinical data, and indeed, as we earlier this year released promising data from our ongoing Ph.2 studies, we have experienced that increased interest. http://tinyurl.com/cwyo6f
RE "IMHO, the "market" will pay attention to this stock starting in April,May and June"
At least you're consistent BOT. You always place the good things for shareholders a few months out. Unfortunately, you've been doing that for years and have a very poor record.
"Most significant March event will be the long awaited publication of two years of Duke/Haynes work with the Company’s several anti-PS antibodies" (FEb 2008)
News 
Market Data 
Discover 
AI
